EICOSANOID RESEARCH FOUNDATION C/O… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2004

Principal Officer

CHARLES SERHAN

Phone

3135772999

Tax Period

2023-01-01 to 2023-12-31

EICOSANOID RESEARCH FOUNDATION C/O KRISHNARAO MADDIPATI, founded in 2004, is a micro nonprofit in the Medical Research sector that reported $20K in total revenue in fiscal year 2023. Revenue fell 92% from the prior year — a significant decline worth monitoring. Expenses of $26K exceeded revenue, resulting in a 32% operating deficit.

Mission

THE PRIMARY EXEMPT PURPOSE OF THE EICOSANOID RESEARCH FOUNDATION IS TO PROVIDE A FORUM FOR THE DISSEMINATION OF THE LATEST SCIENTIFIC INFORMATION ON BIOACTIVE LIPIDS IN HEALTH AND DISEASE AS IT RELATES TO CANCER, INFLAMATION AND INFLAMATION INDUCED DISEASES SUCH AS CARDIOVASCULAR, DIABETES, PSORIASIS AND ALZHEIMER'S. THIS PURPOSE IS ACCOMPLISHED THROUGH THE ORGANIZATION'S BIENNIAL CONFERENCE. THE EICOSANOID RESEARCH FOUNDATION SPONSORS BIENNIAL CONFERENCES HIGHLIGHTING DATA AT THE CUTTING EDGE OF MEDICAL SCIENCE. DURING THESE CONFERENCES NEW DRUGS AND MEDICATIONS ARE DISCUSSED, DATA ON CLINICAL TRIALS IS EXAMINED AND SCIENTISTS FROM ALL OVER THE WORLD INTERACT TO ENHANCE THEIR COLLABORATIVE RESEARCH EFFORTS. THE GOAL OF THIS MEETING SERIES IS TO PROMOTE THE EXCHANGE OF INFORMATION AND IDEAS AMONG INTERNATIONAL SCIENTISTS OF DIVERSE BACKGROUNDS. THE MAIN PURPOSE OF THE EICOSANOID RESEARCH FOUNDATION IS TO RAISE FUNDS TO SPONSOR THE INTERNATIONAL CONFERENCE ON BIOACTIVE LIPIDS IN CANCER,

Program Service Accomplishments

Program 1

Expenses: $25,051

BIENNIAL BIOACTIVE LIPIDS CONFERENCE: THE ORGANIZATION HELD AN INFORMATIVE AND SUCCESSFUL CONFERENCE IN THE FALL OF 2022 RELATING TO THE DISSEMINATION OF THE LATEST SCIENTIFIC AND MEDICAL INFORMATION ON BIO-ACTIVE LIPIDS IN HEALTH AND DISEASE, INCLUDING CANCER. THIS WAS THE 17TH INTERNATIONAL CONFERENCE SCHEDULED IN NEW ORLEANS, LOUISIANA, USA FROM OCTOBER 30 - NOVEMBER 2, 2022. THE CONFERENCE SUCCESSFULLY PROMOTED THE EXCHANGE OF IDEAS AND THEORIES IN THIS AREA AMONG SCIENTISTS AND MEDICAL PROFESSIONALS AROUND THE WORLD, IN AN EFFORT TO FIND A CURE FOR DIEASE AND THE RESOLUTIN OF IMFLAMMATORY DISEASES.

Program 2

ANNUAL WAYNE STATE UNIVERSITY LIPIDS SYMPOSIUM: THE WAYNE STATE UNIVERSITY LIPIDS SYMPOSIUM ADDRESSES THE VITAL ROLES OF LIPIDS IN CELLULAR PROCESSES REQUIRED FOR NORMAL PHYSIOLOGICAL FUNCTION. THE 7TH WSU LIPIDS SYMPOSIUM WAS SCHEDULED FOR MAY 13, 2020 IN THE STUDENT BALLROOM ON THE MAIN CAMPUS OF WAYNE STATE UNIVERSITY. DUE TO THE COVID-19 PANDEMIC, THE EVENT WAS CANCELED. THE SYMPOSIUM HAS BEEN SUSPENDED SINCE THAT POINT, BUT IS CURRENTLY EXPECTED TO RESUME IN EITHER 2023 OR 2024. PREVIOUSLY, THE (6TH) WSU LIPIDS SYMPOSIUM WAS HELD IN THE STUDENT CENTER BALLROOM ON THE MAIN CAMPUS OF WAYNE STATE UNIVERSITY ON MAY 7, 2019 AND WAS WELL ATTENDED.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $18,956

Program Service Revenue $0

Investment Income $2

Other Revenue $1,122

TOTAL REVENUE $20,080

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $25,051

Other Expenses $26,426

TOTAL EXPENSES $26,426

Year-over-Year Comparison

	2023	2022	Change
Revenue	$20,080	$265,748	-0.9%
Expenses	$26,426	$332,097	-0.9%
Net Income	$-6,346	$-66,349	-0.9%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
CHARLES SERHAN	PRESIDENT	N/A	Officer	$0	$0	$0
KRISHNARAO MADDIPATI	TREASURER	N/A	Director	$0	$0	$0
MAKOTO ARITA	DIRECTOR	N/A	Director	$0	$0	$0
EDWARD DENNIS	DIRECTOR	N/A	Director	$0	$0	$0
GABOR TIGYI	DIRECTOR	N/A	Director	$0	$0	$0
TAKEHIKO YOKOMIZO	DIRECTOR	N/A	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2023	$20,080	$26,426	$10,801	$-6,346
2022	$265,748	$332,097	$17,889	$-66,349
2019	$261,031	$226,279	$77,621	$34,752

EICOSANOID RESEARCH FOUNDATION C/O KRISHNARAO MADDIPATI